{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-338068","form_type":"8-K","ticker":"SRZN","cik":"0001824893","company_name":"Surrozen, Inc./DE","filed_at":"2026-08-06T20:15:55+00:00","discovered_at":"2026-08-06T20:17:00.205920+00:00","generated_at":"2026-08-06T20:19:46.852809+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Surrozen reports Q2 2026 results; IND for SZN-8141 planned by Q3 end; PTAB denies Merck petition","bullets":["Planned IND submission for SZN-8141 in DME by end of Q3 2026; DUET Phase 1b/2a to start by year-end 2026 with initial data in H2 2027.","PTAB denied Merck's post-grant review petition challenging Surrozen's U.S. Patent No. 12,297,278, reinforcing IP position.","Boehringer Ingelheim milestone triggered $5.0M collaboration revenue in Q2 2026 (vs $0 in Q2 2025).","Cash and cash equivalents $102.0M as of June 30, 2026, down from $106.9M as of March 31, 2026.","Net income $50.2M (including $59.6M non-cash gains) vs $39.7M (including $47.6M non-cash gains) in Q2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-338068","json":"https://secwatch.observer/filing/0001193125-26-338068.json","markdown":"https://secwatch.observer/filing/0001193125-26-338068.md","text":"https://secwatch.observer/filing/0001193125-26-338068.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1824893/000119312526338068/0001193125-26-338068-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1824893/000119312526338068/srzn-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:19:46.852809+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}